摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

15-nor-8,13-epoxy-1α,6β,7β,9α-tetrahydroxy-labdan-11-one | 93108-94-2

中文名称
——
中文别名
——
英文名称
15-nor-8,13-epoxy-1α,6β,7β,9α-tetrahydroxy-labdan-11-one
英文别名
(4aR,5S,6S,6aS,10S,10aR,10bS)-5,6,10,10b-tetrahydroxy-3,3,4a,7,7,10a-hexamethyl-5,6,6a,8,9,10-hexahydro-2H-benzo[f]chromen-1-one
15-nor-8,13-epoxy-1α,6β,7β,9α-tetrahydroxy-labdan-11-one化学式
CAS
93108-94-2
化学式
C19H32O6
mdl
——
分子量
356.459
InChiKey
UFXXTMNQSAPQER-XSKDXSMHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    25
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.95
  • 拓扑面积:
    107
  • 氢给体数:
    4
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Novel labdane derivatives, process for the preparation thereof, and pharmaceutical compositions containing labdane derivatives
    申请人:SCHERING CORPORATION
    公开号:EP0116713A1
    公开(公告)日:1984-08-29
    This invention relates to a pharmaceutical composition eliciting an antiallergic andior bronchodilatory effect, which comprises a compound of general formula I including the 5,6 and 6,7 dehydro derivatives, in the free form or in the form of its solvate, wherein U is =O or (H,R1) ; V is =0 or (H,R2); wherein R, is H or OR11, wherein R11 is H or acyl, R2 is H, OR11, OSO2R' or OR', wherein R' is alkyl; or when R, and R2 are taken together they may form R3 is hydrogen, alkyl, CH20H, CHO, CO2R15, -CH=CR16R17, -C≡C-R18, -CHOH-C≡C-R19 ; -CH=C=CHR19, -CH=H-OR19, wherein Z is O or -CH=N-NDE or -CH(ZR20)2 wherein Z is defined as above; R4 is H or OH; R5 is OH; or when R4 and R5 are taken together they may form wherein Z is defined as above; X is 0 or H'OR" wherein R" is H, carboxylic acyl or trifluoroacetyl; Q is hydrogen, chlorine or bromine; or Q together with R3 may form a bond between the carbon atoms of positions 12 and 13; whereby in the 5,6-dehydro-derivatives of formula I R1 is H and in the 6,7-dehydro-derivatives of formula I R, and R2 are H; and wherein R11, R13, R14, T15, R16, R17. R18, R19, R20, A, B, D, and E are as defined in the claims. Part of the compounds of formula I are new compounds.
    本发明涉及一种具有抗过敏和支气管扩张作用的药物组合物,它包括通式 I 的化合物 包括 5、6 和 6、7 脱氢衍生物,以游离形式或其溶解物形式存在、 其中 U 为 =O 或 (H,R1) ; V 为 =0 或 (H,R2); 其中 R 是 H 或 OR11,其中 R11 是 H 或酰基,R2 是 H、OR11、OSO2R' 或 OR',其中 R' 是烷基;或者当 R 和 R2 结合在一起时,它们可以形成 R3 是氢、烷基、CH20H、CHO、CO2R15、-CH=CR16R17、-C≡C-R18、-CHOH-C≡C-R19 ; -CH=C=CHR19,-CH=H-OR19、 其中 Z 为 O 或 -CH=N-NDE或-CH(ZR20)2,其中 Z 定义如上; R4 是 H 或 OH; R5 是 OH;或当 R4 和 R5 合在一起可形成 其中 Z 的定义同上; X 是 0 或 H'OR",其中 R "是 H、羧酰基或三氟乙酰基; Q 是氢、;或 Q 与 R3 可在位置 12 和 13 的碳原子之间形成键; 式 I 的 5、6-脱氢-衍生物中 R1 是 H,而式 I 的 6、7-脱氢-衍生物中 R 和 R2 是 H; 其中 R11、R13、R14、T15、R16、R17.R18、R19、R20、A、B、D 和 E 如权利要求中所定义。 部分式Ⅰ化合物为新化合物。
  • KREUTNER, WILLIAM;GREEN, MICHAEL J.;SHUE, HO-JANE;SAKSENA, ANIL K.
    作者:KREUTNER, WILLIAM、GREEN, MICHAEL J.、SHUE, HO-JANE、SAKSENA, ANIL K.
    DOI:——
    日期:——
  • DELPECH, BERNARD;LETT, ROBERT
    作者:DELPECH, BERNARD、LETT, ROBERT
    DOI:——
    日期:——
  • DELPECH, BERNARD;LETT, ROBERT, TETRAHEDRON LETT., 28,(1987) N 35, 4061-4064
    作者:DELPECH, BERNARD、LETT, ROBERT
    DOI:——
    日期:——
  • METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP
    申请人:Abraham Soman N.
    公开号:US20110171195A1
    公开(公告)日:2011-07-14
    Methods and compositions are provided for treating a urinary tract infection (UTI). The methods involve administering to a subject in need thereof a cAMP elevator or agent that mimics cAMP, particularly a labdane diterpene such as forskolin or a derivative or analog thereof in a therapeutically effective amount to treat a UTI. The methods may further include administration of at least one cAMP elevator in combination with one or more additional active compounds from other classes of therapeutic agents, such as antimicrobial agents or cholesterol lowering drugs. Compositions of the invention include pharmaceutical compositions and kits for treating a UTI in a subject in need thereof that include therapeutically effective amounts of at least two cAMP elevators, particularly where one of the cAMP elevators is a labdane diterpene such as forskolin or a derivative or analog thereof. In particular, the compositions and kits may also include at least one cAMP elevator in combination with one or more additional active compounds from other classes of therapeutic agents, such as antimicrobial agents or cholesterol lowering drugs.
查看更多